Alert: Did You Miss Out on This Game-Changing Move by Aurora Cannabis (TSX:ACB)?

Billionaire investor and consumer goods expert Nelson Peltz just teamed up with Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB). Here’s why that’s a very big deal.

| More on:
Business people shaking hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Billionaire Nelson Peltz is truly a titan in the world of corporate finance. And I’m not just saying that because we share a first name, either.

Peltz is the founder of Trian Fund Management, which is an activist investment hedge fund. Trian’s strategy is pretty simple; Peltz and his team identify a company that can unlock shareholder value by making a few simple moves like selling off an underperforming division. The fund then acquires a stake in the company and starts a vocal campaign selling investors on its vision. When successful, this culminates with Peltz getting a seat on a company’s board and the plan is executed. Trian takes its profit and moves on to the next opportunity.

One look at Trian’s success and it’s obvious the formula works. The fund has more than US$10 billion under management, and Peltz is comfortably a billionaire. His net worth is reportedly close to US$2 billion.

Needless to say, the 76-year-old billionaire has accomplished enough to be one of the top investors of all time. And now Aurora Cannabis (TSX:ACB)(NYSE:ACB) has him on its side, agreeing to a deal that gives Peltz a board seat in exchange for stock options.

Here’s why this is a very big deal.

The skinny

The Aurora/Peltz agreement works something like this: Peltz will become a senior advisor for the burgeoning marijuana producer, assisting management in negotiating and entering partnerships to expand into other parts of the marijuana market.

In exchange for his expertise, Peltz will receive 19.96 million stock options that will allow him to buy stock at $10.34 per share. Investors should keep in mind that the closing price for Aurora the evening before this deal was announced was $10.64, although the stock did spike some 13% on the news to end Wednesday’s trading day at $12.02.

This means Peltz’s options have already become in the money and are already worth $33.5 million — not bad for a day’s work.

If Peltz exercises the options, he would immediately become Aurora’s second-largest shareholder.

Why this matters

Most of Peltz’s most successful investments have come from the consumer products sector, including stakes in Kraft Foods, Heinz, Mondelez, Wendy’s, and Pepsico. Some of these positions were of the more passive variety, where Peltz was just a regular shareholder. But most of the time Trian’s CEO would get himself elected to the board of directors, where he could help shape corporate direction.

This is exactly what’s happening today with Aurora. Peltz is in the position to use his considerable clout in the consumer products industry to help Aurora with everything from marketing to branding to partnering with certain brands to promote marijuana-infused drinks and snacks.

Aurora is getting this expertise for the mere price of 20 million stock options. Sure, issuing equity has a cost, but it creates the perfect incentive for Peltz to work his magic. If the stock tanks, then Peltz’s stock options crater along with it. These are the kinds of arrangements shareholders want to see.

Peltz also sounds pretty bullish on the marijuana sector in general, saying in a press release, “I believe that Canadian licensed producers, and Aurora in particular, are well positioned to lead in the development of the international cannabis industry as regulations evolve, with a strong, globally replicable operating model.”

In other words, one of the world’s best investors is bullish on cannabis and even more excited about Aurora specifically. No wonder the stock rose so much. This is great news for the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nelson Smith owns shares of Pepsico.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »